To The Moon

Revenue: Reported annual revenue of $7.379 million for 2023.Net Loss: Net loss widened to $82.465 million, or $0.57 per share.Research and Development Expenses: R&D expenses decreased to $68.142 million from $81.054 million in the previous year.General and Administrative Expenses: G&A expenses reduced to $22.584 million from $29.386 million in 2022.Cash Position: Cash, cash equivalents, and restricted cash totaled $34.755 million, down from $46.013 million at the end of 2022.New Leadership: Steven Lo appointed as President, CEO, and Board Member.Operational Progress: Preparing for a Phase 2b study of oral COVID-19 vaccine and expecting Phase 1 norovirus study data in mid-2024.On March 14, 2024, Vaxart Inc , a clinical-stage biotechnology company, released its 8-K filing, detailing its financial results for the full year ended December 31, 2023. The company, known for developing oral recombinant vaccines, reported a net loss of $82.465 million or $0.57 per share, compared to a net loss